These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 30410348)

  • 1. Targeting VEGF pathway to normalize the vasculature: an emerging insight in cancer therapy.
    Wu JB; Tang YL; Liang XH
    Onco Targets Ther; 2018; 11():6901-6909. PubMed ID: 30410348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside.
    Arjaans M; Schröder CP; Oosting SF; Dafni U; Kleibeuker JE; de Vries EG
    Oncotarget; 2016 Apr; 7(16):21247-58. PubMed ID: 26789111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normalization of Tumor Vasculature by Oxygen Microbubbles with Ultrasound.
    Ho YJ; Chu SW; Liao EC; Fan CH; Chan HL; Wei KC; Yeh CK
    Theranostics; 2019; 9(24):7370-7383. PubMed ID: 31695774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
    Shinkaruk S; Bayle M; Laïn G; Déléris G
    Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):95-117. PubMed ID: 12678905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor as a therapeutic target in cancer.
    Bergsland EK
    Am J Health Syst Pharm; 2004 Nov; 61(21 Suppl 5):S4-11. PubMed ID: 15552621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends and Challenges in Tumor Anti-Angiogenic Therapies.
    Jászai J; Schmidt MHH
    Cells; 2019 Sep; 8(9):. PubMed ID: 31540455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor refractoriness to anti-VEGF therapy.
    Ribatti D
    Oncotarget; 2016 Jul; 7(29):46668-46677. PubMed ID: 27081695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
    Hicklin DJ; Ellis LM
    J Clin Oncol; 2005 Feb; 23(5):1011-27. PubMed ID: 15585754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
    Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X
    Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor angiogenesis and anti-angiogenic therapies.
    Shahneh FZ; Baradaran B; Zamani F; Aghebati-Maleki L
    Hum Antibodies; 2013; 22(1-2):15-9. PubMed ID: 24284305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of vascular endothelial growth factor (VEGF) in tumor angiogenesis and early clinical development of VEGF-receptor kinase inhibitors.
    Verheul HM; Pinedo HM
    Clin Breast Cancer; 2000 Sep; 1 Suppl 1():S80-4. PubMed ID: 11970755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor vasculature remolding by thalidomide increases delivery and efficacy of cisplatin.
    Shen Y; Li S; Wang X; Wang M; Tian Q; Yang J; Wang J; Wang B; Liu P; Yang J
    J Exp Clin Cancer Res; 2019 Oct; 38(1):427. PubMed ID: 31656203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aflibercept: a novel VEGF targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple tumors.
    Sharma T; Dhingra R; Singh S; Sharma S; Tomar P; Malhotra M; Bhardwaj TR
    Mini Rev Med Chem; 2013 Apr; 13(4):530-40. PubMed ID: 23317499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor angiogenesis and vascular normalization: alternative therapeutic targets.
    Viallard C; Larrivée B
    Angiogenesis; 2017 Nov; 20(4):409-426. PubMed ID: 28660302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF).
    Byrne AM; Bouchier-Hayes DJ; Harmey JH
    J Cell Mol Med; 2005; 9(4):777-94. PubMed ID: 16364190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
    Jain RK
    Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient VEGF targeting delivery of DOX using Bevacizumab conjugated SiO
    Zhu R; Wang Z; Liang P; He X; Zhuang X; Huang R; Wang M; Wang Q; Qian Y; Wang S
    Acta Biomater; 2017 Nov; 63():163-180. PubMed ID: 28923539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches.
    Ayoub NM; Jaradat SK; Al-Shami KM; Alkhalifa AE
    Front Pharmacol; 2022; 13():838133. PubMed ID: 35281942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
    Leite de Oliveira R; Hamm A; Mazzone M
    Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.